Logo image of AGFB.BR

AGFA-GEVAERT NV (AGFB.BR) Stock Fundamental Analysis

EBR:AGFB - Euronext Brussels - BE0003755692 - Common Stock - Currency: EUR

0.901  +0 (+0.11%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AGFB. AGFB was compared to 12 industry peers in the Health Care Technology industry. The financial health of AGFB is average, but there are quite some concerns on its profitability. AGFB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AGFB had negative earnings in the past year.
AGFB had a negative operating cash flow in the past year.
In the past 5 years AGFB reported 4 times negative net income.
AGFB had a negative operating cash flow in each of the past 5 years.
AGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFAGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

1.2 Ratios

AGFB has a Return On Assets of -6.75%. This is comparable to the rest of the industry: AGFB outperforms 41.67% of its industry peers.
With a Return On Equity value of -28.88%, AGFB perfoms like the industry average, outperforming 41.67% of the companies in the same industry.
Industry RankSector Rank
ROA -6.75%
ROE -28.88%
ROIC N/A
ROA(3y)-8.91%
ROA(5y)0.06%
ROE(3y)-32.3%
ROE(5y)1.63%
ROIC(3y)N/A
ROIC(5y)N/A
AGFB.BR Yearly ROA, ROE, ROICAGFB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

AGFB's Operating Margin has declined in the last couple of years.
The Gross Margin of AGFB (31.11%) is worse than 66.67% of its industry peers.
In the last couple of years the Gross Margin of AGFB has remained more or less at the same level.
AGFB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.11%
OM growth 3Y-1.64%
OM growth 5Y-16.64%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.88%
AGFB.BR Yearly Profit, Operating, Gross MarginsAGFB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

5

2. Health

2.1 Basic Checks

AGFB does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGFB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, AGFB has less shares outstanding
The debt/assets ratio for AGFB is higher compared to a year ago.
AGFB.BR Yearly Shares OutstandingAGFB.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
AGFB.BR Yearly Total Debt VS Total AssetsAGFB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

AGFB has an Altman-Z score of 2.00. This is not the best score and indicates that AGFB is in the grey zone with still only limited risk for bankruptcy at the moment.
AGFB has a Altman-Z score of 2.00. This is in the better half of the industry: AGFB outperforms 75.00% of its industry peers.
AGFB has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
AGFB has a Debt to Equity ratio of 0.44. This is in the better half of the industry: AGFB outperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 2
ROIC/WACCN/A
WACC8.82%
AGFB.BR Yearly LT Debt VS Equity VS FCFAGFB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.00 indicates that AGFB has no problem at all paying its short term obligations.
AGFB has a better Current ratio (2.00) than 75.00% of its industry peers.
A Quick Ratio of 1.26 indicates that AGFB should not have too much problems paying its short term obligations.
The Quick ratio of AGFB (1.26) is better than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.26
AGFB.BR Yearly Current Assets VS Current LiabilitesAGFB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

3

3. Growth

3.1 Past

AGFB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.27%, which is quite good.
AGFB shows a decrease in Revenue. In the last year, the revenue decreased by -1.04%.
The Revenue for AGFB have been decreasing by -10.44% on average. This is quite bad
EPS 1Y (TTM)11.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1911.52%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y-13.53%
Revenue growth 5Y-10.44%
Sales Q2Q%3.83%

3.2 Future

Based on estimates for the next years, AGFB will show a very strong growth in Earnings Per Share. The EPS will grow by 54.87% on average per year.
The Revenue is expected to grow by 2.94% on average over the next years.
EPS Next Y112.7%
EPS Next 2Y71.82%
EPS Next 3Y54.87%
EPS Next 5YN/A
Revenue Next Year2.32%
Revenue Next 2Y2.46%
Revenue Next 3Y2.94%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGFB.BR Yearly Revenue VS EstimatesAGFB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
AGFB.BR Yearly EPS VS EstimatesAGFB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGFB. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 66.27, the valuation of AGFB can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as AGFB.
AGFB is valuated expensively when we compare the Price/Forward Earnings ratio to 21.94, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 66.27
AGFB.BR Price Earnings VS Forward Price EarningsAGFB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGFB.BR Per share dataAGFB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AGFB's earnings are expected to grow with 54.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y71.82%
EPS Next 3Y54.87%

More info and screens

0

5. Dividend

5.1 Amount

AGFB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGFA-GEVAERT NV

EBR:AGFB (5/22/2025, 4:08:13 PM)

0.901

+0 (+0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-27 2025-08-27
Inst Owners52.83%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap139.49M
Analysts75.56
Price Target1.19 (32.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.41%
Min Revenue beat(2)-5.11%
Max Revenue beat(2)-1.72%
Revenue beat(4)0
Avg Revenue beat(4)-5.72%
Min Revenue beat(4)-11.52%
Max Revenue beat(4)-1.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)176.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.57%
Revenue NY rev (3m)-1.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 66.27
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 1.81
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)0.01
Fwd EY1.51%
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS7.35
BVpS2.08
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.75%
ROE -28.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.11%
FCFM N/A
ROA(3y)-8.91%
ROA(5y)0.06%
ROE(3y)-32.3%
ROE(5y)1.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-1.64%
OM growth 5Y-16.64%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.88%
F-Score2
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.14%
Cap/Sales 3.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 1.26
Altman-Z 2
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)78.36%
Cap/Depr(5y)64.97%
Cap/Sales(3y)3.26%
Cap/Sales(5y)2.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1911.52%
EPS Next Y112.7%
EPS Next 2Y71.82%
EPS Next 3Y54.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y-13.53%
Revenue growth 5Y-10.44%
Sales Q2Q%3.83%
Revenue Next Year2.32%
Revenue Next 2Y2.46%
Revenue Next 3Y2.94%
Revenue Next 5YN/A
EBIT growth 1Y-444.44%
EBIT growth 3Y-14.94%
EBIT growth 5Y-25.35%
EBIT Next Year235.46%
EBIT Next 3Y66.5%
EBIT Next 5YN/A
FCF growth 1Y23.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.67%
OCF growth 3YN/A
OCF growth 5YN/A